[Class I antiarrhythmic drugs: mechanisms, contraindications, and current indications]
| Autor: | C, Pott, D G, Dechering, A, Muszynski, S, Zellerhoff, A, Bittner, K, Wasmer, G, Mönnig, L, Eckardt |
|---|---|
| Jazyk: | němčina |
| Rok vydání: | 2010 |
| Předmět: |
Heart Failure
Dose-Response Relationship Drug Contraindications Adrenergic beta-Antagonists Myocardial Infarction Administration Oral Arrhythmias Cardiac Electrocardiography Pregnancy Atrial Fibrillation Tachycardia Supraventricular Tachycardia Ventricular Humans Tachycardia Atrioventricular Nodal Reentry Drug Therapy Combination Female Infusions Intravenous Anti-Arrhythmia Agents Randomized Controlled Trials as Topic Sodium Channel Blockers |
| Zdroj: | HerzschrittmachertherapieElektrophysiologie. 21(4) |
| ISSN: | 1435-1544 |
| Popis: | Class I antiarrhythmic drugs are sodium channel inhibitors that act by slowing myocardial conduction and, thus, interrupting or preventing reentrant arrhythmia. Due to proarrhythmic effects and the risk of ventricular tachyarrhythmia, class I antiarrhythmics should not be administered in patients with structural heart disease. Nevertheless, there remains a broad spectrum of arrhythmias--among the most common being atrial fibrillation--that can successfully be treated with class I antiarrhythmic drugs. This review gives an overview on the classification, antiarrhythmic mechanisms, indications, side effects, and application modes of class I antiarrhythmic drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink